General Information of Drug (ID: DMDYZRS)

Drug Name
BPS-804 Drug Info
Synonyms Anti-sclerostin antibody (osteoporosis/hypophophatasia), Novartis
Indication
Disease Entry ICD 11 Status REF
Metabolic bone disease FB8Y Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMDYZRS

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Sclerostin (SOST)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Romosozumab DMFJZN0 Postmenopausal osteoporosis FB83.11 Approved [3]
UX143 DM89NIB Osteogenesis imperfecta LD24.K0 Phase 3 [4]
LY2541546 DMTVU2Q Osteoporosis FB83.0 Phase 2 [5]
AMG 167 DMUETI2 Osteoporosis FB83.0 Phase 1 [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sclerostin (SOST) TTYRO4F SOST_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT01806610) Study of Safety and Tolerability of BPS804 in Patients With Late-stage Chronic Kidney Disease. U.S. National Institutes of Health.
2 WO patent application no. 2010,1001,79, Self-forming gel system for sustained drug delivery.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4 Clinical pipeline report, company report or official report of Ultragenyx Pharmaceutical
5 Rat-specific decreases in platelet count caused by a humanized monoclonal antibody against sclerostin. Toxicol Sci. 2012 Feb;125(2):586-94.
6 Osteoporosis - a current view of pharmacological prevention and treatment. Drug Des Devel Ther. 2013; 7: 435-448.